Cellular and antibody response in GMZ2-vaccinated Gabonese volunteers in a controlled human malaria infection trial

Table 2 Cox proportional analysis pre-immunization

	Risk to be treated after CHMI
	Cell frequency (Pre-immunization)			Estimated cell number (Pre-immunization)
	HR	95%CI	p value	HR	95%CI	p value
IFN_γ⁺IL2⁺TNFα⁺ CD4⁺ T	1.49	0.92–2.40	0.10	1.02	0.99–1.04	0.13
IFN_γ⁺IL2⁺ CD4⁺ T	0.92	0.52–1.64	0.78	0.98	0.79–1.20	0.86
IFN_γ⁺TNFα⁺ CD4⁺ T	1.28	0.46–3.55	0.63	0.99	0.95–1.03	0.85
IL2⁺TNFα⁺ CD4⁺ T	1.15	0.58–2.27	0.68	1.00	0.99–1.01	0.56
IgG positive CD20 + B cell	0.85	0.56–1.10	0.16	1.00	0.99–1.00	0.59
GMZ2-specific B cells	1.01	0.94–1.1	0.64	1.00	0.99–1.00	0.07
CD27 negative GMZ2-specific B cells	1.01	0.91–1.12	0.74	1.00	0.99–1.00	0.21
CD27 positive GMZ2-specific B cells	1.39	0.98–1.96	0.06	1.01	0.99–1.02	0.07

Treatment after CHMI was administered to those who developed malaria or to those whose parasitaemia was more than 1000 parasites per µL.
p value was significant when less than 0.05
CI confidence interval, HR hazard ratio.

ISSN: 1475-2875